Miles W. Griffis
-
Research updates, December 2
A large retrospective cohort study of over 18,000 live births found that infants exposed to SARS-CoV-2 infection during pregnancy were more likely to have adverse neurodevelopmental diagnoses by the time they were three years old.
-
Research updates, November 25
A new review paper summarizes the vast global costs of Long COVID. Public health researcher Amit Bansal from the University of Bergen conducted an economic literature analysis and determined that Long COVID is estimated to have an average annual burden of at least $1 trillion globally each year.
-
Research updates, November 18
A new mechanistic study in Science Translational Medicine identifies Epstein-Barr virus (EBV) as a potential trigger of the autoimmune disease systemic lupus erythematosus.
-
Alice Wong, disability activist and luminary, dies at 51
Alice Wong platformed and uplifted people with Long COVID in her final chapter as a lifelong disability advocate and storyteller.
-
Research updates, November 11
The RECOVER-NEURO clinical trial found that “cognitive rehabilitation” failed in treating Long COVID. The National Institutes of Health (NIH) study included 328 people who underwent interventions of either online cognitive training (computer games), a cognitive rehabilitation program, or received electric currents on their heads.
-
Research updates, November 4
The German government is cutting millions of euros in Long COVID funding, according to the German business newspaper Handelsblatt.
-
Research updates, October 28
A small mechanistic study in Frontiers in Immunology analyzed chronic inflammation in COVID-19. Researchers assessed over 70,000 blood cells from eight participants across different disease states.
-
NBA player Kristaps Porziņģis shares POTS diagnosis
Earlier this week, professional basketball player Kristaps Porziņģis shared his diagnosis of postural orthostatic tachycardia syndrome (POTS). The 30-year-old player began facing severe health challenges this spring while playing for the Celtics that made running and exercise extremely difficult. While standing at rest he said his heart rate could be as high as 130. “It…
-
Research updates, October 21
A clinical trial for the anti-inflammatory drug Colchicine did not find the drug effective for Long COVID, according to a new study published in JAMA Internal Medicine. The randomized trial included 346 participants in India who took at least 0.5 milligrams once or twice per day, or a placebo, for 52 weeks.
-
Research updates, October 14
A large electronic health records study found SARS-CoV-2 infection is associated with elevated risks of Human Papillomavirus (HPV)-related cancer.
Follow Us
get the latest long covid news
Trending
Recent ARTICLES
Tags
advocacy arts CDC clinical trials commentary COVID-19 precautions disability essay government policy H5N1 healthcare HHS influenza international Long COVID in children masks and respirators ME ME/CFS medical education national COVID-19 trends NIH NIH RECOVER podcast public health research update science Trump administration updates and events vaccines wastewater surveillance